OncoMatch/Clinical Trials/NCT06592170
Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)
Is NCT06592170 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Linperlisib combination with obinutuzumab for lymphoma.
Treatment: Linperlisib combination with obinutuzumab — This is a single arm, open label, national multicenter clinical study included patients with marginal zone lymphoma patients (MZL) , aim is to evaluate the efficacy and safety of first-line treatment with Linperlisib combined with obinutuzumab in patients with marginal zone lymphoma (MZL).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: pi3k inhibitor
Lab requirements
Blood counts
Hemoglobin (Hb) ≥ 90 g/L; Neutrophil count (ANC) ≥ 1.5 × 10^9/L; Platelets (PLT) ≥ 100 × 10^9/L
Kidney function
Serum creatinine ≤ 1.25 × ULN or Endogenous creatinine clearance rate ≥ 60 mL/min (Cockcroft Gault formula)
Liver function
TBIL < 1.5 x ULN; ALT and AST ≤ 2.5 × ULN
Cardiac function
No ≥ grade 2 myocardial ischemia or myocardial infarction, arrhythmia [including QTc ≥ 450ms (male), QTc ≥ 470ms (female)], and ≥ grade 2 congestive heart failure [NYHA classification]
Possess sufficient bone marrow and organ functions; laboratory tests must meet the following standards: ... Hemoglobin (Hb) ≥ 90 g/L; Neutrophil count (ANC) ≥ 1.5 × 10^9/L; Platelets (PLT) ≥ 100 × 10^9/L; TBIL < 1.5 x ULN; ALT and AST ≤ 2.5 × ULN; Serum creatinine ≤ 1.25 × ULN or Endogenous creatinine clearance rate ≥ 60 mL/min (Cockcroft Gault formula); INR ≤ 1.5 × ULN; APTT ≤ 1.5 × ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06592170 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages